4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001714899-23-000066
President and CEO sold 25,000 shares at an average $25.15 ($628,720)
- President and CEO acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Watts Ryan J. · President and CEO
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-20 | Exercise or conversion : show line 1 in the form | +200 | $0.68 | $136 | 2,240,113 | I |
| 2023-04-20 | Sale : show line 2 in the form | −200 | $25.00 | $5,000 | 2,239,913 | I |
| 2023-04-21 | Exercise or conversion : show line 3 in the form | +24,800 | $0.68 | $16,864 | 2,264,713 | I |
| 2023-04-21 | Sale : show line 4 in the form | −24,800 | $25.15 | $623,720 | 2,239,913 | I |
| Open-market sales · 25,000 sh · avg $25.15 · $628,720 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-04-20 | Exercise or conversion : show line 5 in the form Stock Option (right to buy) | −200 | 1,195,417 | D |
| 2023-04-21 | Exercise or conversion : show line 6 in the form Stock Option (right to buy) | −24,800 | 1,170,617 | D |
Loading xslF345X04/wf-form4_168237782624985.xml…